PATENT CLAIM ANALYSIS

Application Number: 15758187
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-01
Patent Classification: ["424", "185100"]

Abstract:
The present disclosure relates to CCL22 as a novel T cell target in cancer immunosuppression.

Claim (Index 63):
The method of  claim 62 , wherein the cancer treatment is selected from the group consisting of chemotherapy, radiotherapy, treatment with immunostimulating substances, treatment with an anti cancer agent, gene therapy, treatment with antibodies and treatment using dendritic cells.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 90.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14352407', '15231075', '12988124', '10580016', '13031396']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8201661708489708
- 35 USC 102 Novelty (BERT): 0.5533933386812898
- Combined Prediction Score: 0.7934888876322027
- Mean Citation Score: 418.076916
- Max Citation Score: 477.45294
- Similarity Product: 297.7516088315535

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test